Regulus Therapeutics (RGLS) Misses Q1 EPS by 7c

Regulus Therapeutics (NASDAQ: RGLS) reported Q1 EPS of ($0.29), $0.07 worse than the analyst estimate of ($0.22).

For earnings history and earnings-related data on Regulus Therapeutics (RGLS) click here.

You May Also Be Interested In

• Micron offers Taiwan workers up to 68-month bonuses as strike threat looms
• Kroger (KR) Tops Q2 EPS by 3c, Misses on Revenue; Offers FY27 EPS Guidance
• Macy's (M) Stock: Street Underestimates Earnings Pressure From Share Loss, Says Analyst